Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317489 | 0.90 | CYP3A4 (0.56) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL3992623 | 0.82 | CYP3A4 (0.56) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL14978818 | 0.81 | CYP2D6 (0.45) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL19647140 | 0.81 | CYP2D6 (0.45) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL14978820 | 0.81 | CYP2D6 (0.45) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| Hydrochloric Acid SCHEMBL25412712 | 0.80 | CYP3A4 (0.54) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL14349296 | 0.79 | CYP3A4 (0.50) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL15447121 | 0.78 | SIGMAR1 (0.61) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL4782995 | 0.78 | OPRL1 (0.54) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL2918565 | 0.78 | SIGMAR1 (0.65) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP3A4 2566/4885HSD17B10 684/4885SIGMAR1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.